A fully automated segmentation application on the Blackford Platform™ that enables clinicians to evaluate brain structure volume changes relevant to neurodegenerative disease. NeuroQuant® and NeuroQuant MS™ analyses provide clinicians with accurate and reliable brain structure volumes and normative percentiles to help diagnose and monitor disease progression and treatment outcomes in patients with neurodegenerative disorders.
Benefits
NeuroQuant: Objective assessment
Provides reliable and reproducible quantitative data to help clinicians assess patients’ prognoses and clinical courses
NeuroQuant: Effective assessment of neurodegeneration
Helps clinicians identify and assess neurodegeneration in its earliest stages, aiding treatment and lifestyle planning for patients
NeuroQuant: Longitudinal review
Performs ongoing multi-time point evaluations to assess brain structure volume changes over time, within the same report
NeuroQuant MS: Effective evaluation
Allows effortless evaluation of lesions, lesion evolution, and regional and global brain structure volumes
NeuroQuant MS: Quantitative data
Provides quantitative numbers to support the physician’s clinical impression. Quantitative measurements aids in treatment planning, monitoring disease progression, and treatment success
NeuroQuant MS: Global assessment
Combines brain volume and lesion data to aid the assessment, prognoses and clinical courses for a patient
Features
NeuroQuant
- Automatic image segmentation
First FDA-cleared software for volumetric MRI processing. Uses automatic image segmentation from MR images to support medical professionals in quantifying atrophy and assessing neurodegenerative diseases. - Volumetric analysis
Volumetric measurements of brain structures and compares the volumes to age and gender-matched healthy patients in the NeuroQuant normative database. Over a hundred thousand clinical cases have used this software. - Personalized segmentation
Provides personalized segmentation vs. one-size-fits-all for more accurate and consistent brain segmentation in all patients (ages 3-100) and greater scan-to-scan precision for longitudinal follow-up.
NeuroQuant MS
- Quantifies neurodegenerative disease
FDA cleared for volumetric MRI processing of 3D T1 and T2 FLAIR images. Used by medical professionals to support visual interpretations by quantifying lesions and brain volumes to assess demyelinating neurodegenerative disease. - Automatic image segmentation
Automatically segments MR images, calculates lesion burden and provides volumes, counts, and color-coded DICOM overlays of all, new, and enlarging lesions. - Volumetric analysis
Provides volumetric measurements of brain structures and compares the volumes to a normative database adjusted for age, gender and intracranial volume, helping physicians evaluate patients from 3 to 100 years old.
